217 results on '"Pedersen, Mikkel W."'
Search Results
2. Population genomics of the Viking world
3. First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies
4. Postglacial viability and colonization in North America’s ice-free corridor
5. Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation
6. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models
7. Abstract CT274: Individualized APC targeting VB10.NEO cancer vaccines induce broad neoepitope-specific CD8 T cell responses in patients with advanced or metastatic solid tumors: interim results from a phase 1/2a trial
8. Supplementary Materials and Methods from Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance
9. Supplementary Materials and Methods from Sym004, a Novel Anti-EGFR Antibody Mixture, Augments Radiation Response in Human Lung and Head and Neck Cancers
10. Data from Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
11. Supplementary methods from Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms
12. Supplementary Figure 2 from Sym004, a Novel Anti-EGFR Antibody Mixture, Augments Radiation Response in Human Lung and Head and Neck Cancers
13. Data from Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance
14. Supplementary Figure Legends from Sym004, a Novel Anti-EGFR Antibody Mixture, Augments Radiation Response in Human Lung and Head and Neck Cancers
15. Supplementary Figures 1-7 from Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms
16. Data from Sym004, a Novel Anti-EGFR Antibody Mixture, Augments Radiation Response in Human Lung and Head and Neck Cancers
17. Data from Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms
18. Supplementary Tables and Figures from Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance
19. Supplementary Figure S1 from Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
20. Supplementary Figure 1 from Sym004, a Novel Anti-EGFR Antibody Mixture, Augments Radiation Response in Human Lung and Head and Neck Cancers
21. Supplementary Table S2 from Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
22. Supplementary Figure Legend from Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
23. Supplementary Figures S1-8 from Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
24. Supplementary Tables S1-2 from Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
25. Author Correction: Population genomics of the Viking world
26. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression
27. Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab
28. Ancient Human Genomes and Environmental DNA from the Cement Attaching 2,000-Year-Old Head Lice Nits
29. Chiquihuite Cave and America's Hidden Limestone Industries:A Reply to Chatters et al.
30. Ancient Human Genomes and Environmental DNA from the Cement Attaching 2,000-Year-Old Head Lice Nits
31. Chiquihuite Cave and America’s Hidden Limestone Industries: A Reply to Chatters et al.
32. Targeting the ERBB family in cancer: couples therapy
33. Abstract 1797: Preclinical characterization of Sym024, a novel anti-CD73 antibody
34. Lake Sedimentary DNA Research on Past Terrestrial and Aquatic Biodiversity: Overview and Recommendations
35. Lake Sedimentary DNA Research on Past Terrestrial and Aquatic Biodiversity:Overview and Recommendations
36. Deep neural networks identify signaling mechanisms of ErbB-family drug resistance from a continuous cell morphology space
37. Lake Sedimentary DNA Research on Past Terrestrial and Aquatic Biodiversity: Overview and Recommendations
38. Population genomics of the Viking world:[incl. correction]
39. Deep neural networks identify signaling mechanisms of ErbB-family drug resistance from a continuous cell morphology space
40. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells
41. Ancient Human Genomes and Environmental DNA from the Cement Attaching 2,000-Year-Old Head Lice Nits.
42. Hedgehog signaling in small-cell lung cancer: Frequent in vivo but a rare event in vitro
43. Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype
44. EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes
45. Shotgun Environmental DNA, Pollen, and Macrofossil Analysis of Lateglacial Lake Sediments From Southern Sweden
46. New Targets for Detection and Treatment of Small Cell Lung Cancer*
47. Shotgun Environmental DNA, Pollen, and Macrofossil Analysis of Lateglacial Lake Sediments From Southern Sweden
48. Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform
49. Chiquihuite Cave and America’s Hidden Limestone Industries: A Reply to Chatters et al.
50. Archaeal community changes in Lateglacial lake sediments : Evidence from ancient DNA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.